Citing GLP-1 Trial Results in Clinic Marketing: FTC Guidance (2026)

A weight-loss clinic can advertise published GLP-1 trial results when the ad accurately identifies the study, population, treatment conditions, duration, and outcome—and makes clear that the finding is not a promise about the clinic’s patients. The FTC evaluates the ad’s overall impression, including headlines, visuals, testimonials, disclaimers, and landing-page context.

What can a clinic say about GLP-1 trial results?

A clinic may use a published clinical trial as support for an educational statement about what happened in that study. The statement must remain a statement about the study, not a prediction about what prospective patients will experience.

Evidence for one medication, population, treatment duration, lifestyle program, or clinical setting may not substantiate a claim about a different clinic program. The FTC’s health-products guidance says health-related advertising claims generally require competent and reliable scientific evidence. Randomized controlled human clinical trials are often the strongest evidence, but the study must actually support the claim being made.

The practical question is not simply whether the trial is real. It is what an ordinary prospective patient would believe the ad is promising. A citation can be factually accurate and still create a deceptive net impression if the surrounding creative suggests that the clinic delivers the same average result.

Why does the FTC focus on the ad’s net impression?

The FTC looks at the message consumers are likely to take away from the advertisement as a whole. That includes the headline, imagery, charts, before-and-after photographs, physician imagery, testimonials, fine print, and the page a reader reaches after clicking.

A small disclaimer cannot necessarily repair a large promise in the headline. An ad saying “Lose 20% with our program” may still communicate a patient-outcome promise even if a footer says “results vary.” A dramatic body-transformation graphic can imply typicality even when nearby text cites a trial accurately.

Compliant versus noncompliant claim patterns

How should a clinic cite STEP 1, SURMOUNT-1, and SELECT?

Each trial citation should identify enough context to prevent a headline percentage from being mistaken for a guaranteed clinic result. These summaries describe published studies; they are not patient-facing promises.

What did STEP 1 report?

STEP 1 enrolled 1,961 adults with overweight or obesity who did not have type 2 diabetes. Over 68 weeks, participants receiving semaglutide plus lifestyle intervention had an approximately 14.9% mean body-weight change, compared with 2.4% for placebo, according to the PubMed-indexed trial report.

A cautious marketing explanation should identify STEP 1, its population, 68-week duration, lifestyle-intervention setting, comparator, and reported average. It should then state that individual results vary and that the study average is not a promise of clinic or patient outcomes.

What did SURMOUNT-1 report?

SURMOUNT-1 studied 2,539 adults with obesity, or overweight with at least one obesity-related complication, and excluded participants with type 2 diabetes. At 72 weeks, the study reported mean weight reductions of about 15% to 21% across its three tirzepatide treatment arms, compared with 3.1% for placebo, according to its ClinicalTrials.gov record.

The roughly 21% figure is the study’s highest treatment-arm result. It should not appear by itself or be presented as a typical or guaranteed clinic result. The study’s population, treatment arm, conditions, and 72-week duration may not match the clinic’s patients or program.

What did SELECT measure?

SELECT enrolled 17,604 adults with overweight or obesity, established cardiovascular disease, and no diabetes. Its primary evaluation concerned cardiovascular outcomes, not simply a general weight-management promise. The study also reported approximately 9.39% mean body-weight reduction at 104 weeks versus 0.88% with placebo.

That population and endpoint are essential context. A clinic should not use SELECT to suggest that semaglutide is a general cardiovascular-protection product for every person seeking weight management. A cardiovascular finding should not be presented as a guarantee of safety or benefit for an individual prospective patient.

Does FDA approval make a GLP-1 marketing claim acceptable?

FDA approval does not automatically substantiate a claim about a clinic, a program, or an individual outcome. The current Wegovy prescribing information identifies approved uses for chronic weight management in specified adults and adolescents in combination with a reduced-calorie diet and increased physical activity. It also includes a boxed warning concerning thyroid C-cell tumors and contraindications involving a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Those labeling facts do not authorize claims such as “guaranteed results,” “safe for everyone,” “permanent weight loss,” “faster results,” or “no side effects.” Approval also does not establish that a compounded or otherwise different product is the same as an FDA-approved product, or that a clinic’s service produces the outcomes reported in a trial.

Marketing should distinguish the medication’s approved labeling from the clinic’s separate service claims. Clinical decisions belong to independently licensed clinicians, who evaluate whether treatment is appropriate for a particular patient. MDLaunchr provides business and telehealth infrastructure; it does not replace the clinician’s judgment or turn a study result into a program guarantee.

What should a GLP-1 claim-substantiation file contain?

A clinic should maintain a claim-substantiation file before publishing each material ad variation:

1. 1Copy the exact claim. Include the headline, button text, testimonial, chart label, image caption, and landing-page language.
2. 2Identify the evidence. Record the named study, source, population, treatment conditions, duration, comparator, and outcome.
3. 3Compare the study with the program. Note whether the clinic offers the same clinical selection, lifestyle intervention, follow-up, and other relevant conditions. Do not describe a compounded product as the same as or a generic version of a brand product.
4. 4Test the likely takeaway. Ask whether a reasonable prospective patient could read the ad as promising a specific percentage, amount, speed, safety profile, or permanent result.
5. 5Review the creative as a whole. Check images, testimonials, physician imagery, before-and-after content, typography, disclosures, and the destination page.
6. 6Record limitations. Preserve relevant information about discontinuation, adverse events, maintenance, study boundaries, and differences between the evidence and the advertised program.
7. 7Approve every variation. A compliant landing page does not automatically make a noncompliant social ad, search ad, email, or video acceptable.

This documentation is useful for operational review, but it is not a substitute for qualified legal or regulatory advice.

Are GLP-1 patient testimonials allowed in clinic advertising?

Yes, but only when the testimonial and the broader impression it creates are properly substantiated, and when the advertisement does not make an atypical result look typical. Testimonials can communicate both the speaker’s individual result and an implied expectation for other patients.

A testimonial saying “I lost 40 pounds” must be supported as the person’s actual experience, and the broader implication must be supported if viewers could reasonably understand it as a typical result. The FTC’s endorsement and testimonial guidance does not treat a testimonial as a substitute for scientific evidence.

If the result is not typical, the advertisement must clearly and conspicuously disclose the generally expected result or accurately communicate that the experience is atypical. A vague “results may vary” statement may not be enough when the image, headline, or testimonial emphasizes an unusually large outcome.

How do state rules affect national GLP-1 advertising?

The FTC’s federal advertising principles apply nationally, but state medical-practice and professional-discipline rules can add requirements. Ownership, physician control, delegation, telehealth, testimonials, guarantees, and advertising language vary by state.

In New York, Department of Health materials describe several physician-owned or physician-controlled structures for private physician practices. New York Education Law Section 6530 treats advertising or solicitation that is false, fraudulent, deceptive, misleading, sensational, or unsubstantiated as professional misconduct and identifies testimonials and guarantees as problematic categories.

In Texas, Texas Medical Board materials emphasize restrictions on non-physician entities practicing medicine and the physician’s responsibility for patient-specific decisions. Texas also has requirements concerning prescriptive-authority agreements when a physician delegates prescriptive authority to a physician assistant or advanced practice nurse. Marketing should not suggest that a platform, protocol, manager, or supervising physician independently preselects treatment for a patient.

In Florida, Department of Health materials identify false, deceptive, or misleading advertising as a basis for professional discipline and separately address unlicensed practice. A Florida clinic should make clear which licensed medical service is being offered and should avoid presenting a nonclinical business as independently diagnosing, prescribing, or guaranteeing outcomes. The sources reviewed here do not establish a complete Florida corporate-practice rule, so the entity and service structure require separate review.

These examples are not a national rule. A clinic expanding across states should map the patient’s location, clinician licensure, clinical entity, ownership and management structure, prescriptive authority, and advertising review process before launch.

What should a compliant GLP-1 marketing workflow look like?

A workable workflow separates education from outcome promotion:

• Formulary and labeling review: Identify the medications the clinical program may offer and keep approved labeling separate from claims about the service.
• Evidence review: Match each proposed statement to the exact study, population, treatment conditions, duration, and endpoint.
• Program comparison: Document where the clinic’s evaluation, follow-up, lifestyle support, patient selection, and product pathway differ from the cited trial.
• Creative review: Inspect headlines, visuals, testimonials, disclosures, and landing pages for implied promises.
• Clinical governance review: Ensure copy does not suggest that a platform or business makes patient-specific prescribing decisions.
• State review: Apply the rules of the states where patients and clinicians are located; do not treat New York, Texas, or Florida examples as nationwide requirements.
• Version control: Retain the approved copy, source, date, reviewer, and evidence file for each channel.
• Monitoring: Recheck ads after edits, because a new headline or image can change the net impression even when the cited paragraph stays the same.

MDLaunchr is one infrastructure option for clinic owners evaluating how to organize a branded GLP-1 program; independently licensed clinicians make clinical decisions. See the GLP-1 weight management program when you are ready to evaluate the program setup.

Related reading: the full guide this article belongs to, How a Med Spa Can Add Prescription Skincare Telehealth, How an Urgent Care Center Can Add a Weight Management Program.